Journal article
Tenecteplase Treatment and Thrombus Characteristics Associated with Early Reperfusion: An EXTEND-IA TNK Trials Analysis
V Yogendrakumar, L Churilov, P Guha, J Beharry, PJ Mitchell, TJ Kleinig, N Yassi, V Thijs, TY Wu, H Brown, HM Dewey, T Wijeratne, B Yan, G Sharma, PM Desmond, MW Parsons, GA Donnan, SM Davis, BCV Campbell, R Dowling Show all
Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2023
Abstract
Background: Intracranial occlusion site, contrast permeability, and clot burden are thrombus characteristics that influence alteplase-associated reperfusion. In this study, we assessed the reperfusion efficacy of tenecteplase and alteplase in subgroups based on these characteristics in a pooled analysis of the EXTEND-IA TNK trial (Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke). Methods: Patients with large vessel occlusion were randomized to treatment with tenecteplase (0.25 or 0.4 mg/kg) or alteplase before thrombectomy in hospitals across Australia and New Zealand (2015-2019). The primary outcome, early reperfusion, was defined as the absence of retrievable ..
View full abstractGrants
Awarded by Amgen
Funding Acknowledgements
The EXTEND-IA TNK trial (Tenecteplase Versus Alteplase Before Endovascu-lar Therapy for Ischemic Stroke) received funding from the National Health and Medical Research Council Australia (GNT1113352, GNT1111972). Dr Yogen-drakumar is supported by the University of Melbourne, a Canadian Institutes of Health Research Fellowship Award, and a Detweiler Travelling Fellowship Award (Royal College of Physicians and Surgeons of Canada).